According to a recent LinkedIn post from Beacon Biosignals, the company has extended its Series B financing to $97 million, bringing total funding to $132 million. The post indicates that new investors include JSL Health Capital, Samsung Next, Kicker Ventures, and Palo Santo, joining an existing syndicate featuring Innoviva Specialty Therapeutics, Inc., GV, General Catalyst, and others.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post suggests that the additional capital is intended to accelerate development of scalable, at-home EEG hardware and analytics infrastructure for diagnostics, clinical trials, and precision medicine applications. The focus on objective, scalable measurement of brain-based outcomes positions Beacon Biosignals to potentially benefit from emerging psychiatric therapeutics, which could enhance its strategic relevance within neurotechnology, digital health, and brain health markets.
For investors, this expanded funding round signals continued institutional interest and may strengthen the company’s ability to execute on product development and commercial partnerships in clinical research and diagnostics. The participation of prominent venture investors could improve Beacon Biosignals’ visibility and bargaining power with biopharmaceutical and medtech partners, while the emphasis on at-home monitoring aligns with broader industry trends toward decentralized clinical trials and remote patient assessment.